{ }
001122334455554433221100
001122334455554433221100

abbvie acquires nimble therapeutics to enhance autoimmune disease treatment options

AbbVie has acquired Nimble Therapeutics for $200 million, gaining access to an oral peptide drug candidate aimed at treating psoriasis by inhibiting the IL23 receptor. This addition complements AbbVie's existing injectable drug, Skyrizi, and aims to address significant unmet medical needs in autoimmune diseases.

abbvie acquires nimble therapeutics to enhance immune drug pipeline

AbbVie is set to acquire Nimble Therapeutics for $200 million, enhancing its pipeline of oral peptide drugs targeting immune diseases like psoriasis and inflammatory bowel disease. Nimble's lead candidate aims to inhibit IL-23, similar to AbbVie’s Skyrizi, but offers an oral delivery method. This acquisition marks AbbVie’s third buyout of an immune drug developer this year, reflecting a strategic push to strengthen its immunology portfolio.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.